

Monteggio, Switzerland – 1st May 2026

PRESS RELEASE

Microsize and Schedio Group Complete Acquisition of Micro-Macinazione.

Microsize and Schedio Group today announce the successful closing of the acquisition of Micro-Macinazione (MicMac) from Lonza, effective May 1, 2026. The Monteggio site in Ticino is now officially part of Microsize's global platform.

The transaction, first announced in November 2025, has now been successfully completed. With the official transfer of ownership, Mic Mac becomes a fully integrated part of Microsize's international network, alongside the strategic co-investment of Schedio Group. The site will continue to operate under the name **Micro-Macinazione**, preserving the brand and reputation built over more than 30 years serving the pharmaceutical industry.

A Strong Team, Seamless Continuity

The Monteggio workforce remains fully in place through the transition. The highly skilled team, with deep expertise in GMP operations, forms the operational backbone of the site and will play a central role in the months ahead. Existing customers can count on full continuity of services, with no interruption to jet milling and micronization activities for both clinical and commercial supply. *"The closing of this acquisition marks the beginning of a new chapter,"* said **TJ Higley, CEO of Microsize**. *"MicMac is not just a strategic asset — it is a team of people with rare expertise and a quality culture that aligns perfectly with our own. From today, our customers can access GMP micronization capabilities on both sides of the Atlantic, with a single trusted partner."*

Investment and Development

Microsize and Schedio are committed to ongoing investment in the Monteggio site, with plans to further develop its capabilities over time. The combination of Microsize's CDMO experience and Schedio's engineering expertise creates a solid basis for that development, with the shared goal of strengthening the site's offering for pharmaceutical customers across Europe and beyond.

"This closing is a starting point, not a finish line," said **Mattia Wiedemeier, CCO of Schedio Group**. *"Together with Microsize, we will work to bring new capabilities to MicMac over time, building on what is already a strong foundation. The 'Power of Together' is now fully operational."* **Derek Hennecke, Chairman of Microsize**, added: *"Particle size control is a specialized field, and MicMac has earned its reputation in it over decades. With Monteggio and Quakertown, we offer pharmaceutical customers worldwide unparalleled access to specialized expertise in particle size control — a platform dedicated entirely to this field, with the scale and expertise to serve customers at every stage of development, on both sides of the Atlantic."*

ABOUT SCHEDIO

Situated in Ticino, Switzerland, Schedio SA is renowned for its tailor-made equipment emphasizing bioavailability enhancement and ensuring both product and operator protection. They distinguish themselves with their emphasis on simplicity, robust machine and process support, and an unwavering commitment to safety.

The core philosophy of Schedio revolves around a partnership-centric approach, valuing enduring relationships and aiming to enact tangible enhancements in their clients' businesses.

Visit www.schedio.ch

ABOUT MICROSIZE

Microsize is a contract development and manufacturing organization (CDMO) focused exclusively on particle size reduction and control technologies. Founded in 2022 through the acquisition of Lonza's Quakertown site, Microsize is backed by experienced CDMO executives

and investors. The company provides GMP-compliant milling and micronization services to pharmaceutical innovators at all stages of development.

Visit www.microsize.com

PRESS CONTACTS

Schedio SA
Mattia Wiedemeier
Commercial Director
Tel: +41 79 900 62 13
mattia.wiedemeier@schedio.ch

Microsize
TJ Higley
CEO
Tel: 215-536-5605
tjhigley@microsize.com